OncoSec Medical Inc (ONCSQ)

[ahab333]

Here is an update on ONCS ownership from Tutes:

Vanguard boosts shares in ONCS but one sell rating

https://www.americanbankingnews.com/2017/06/15/oncosec-medical-incorporated-oncs-rating-reiterated-by-noble-financial.html

OncoSec Medical Incorporated - Get News & Ratings Daily
Enter your email address below to get the latest news and analysts' ratings for OncoSec Medical Incorporated with our FREE daily email newsletter:

Advertisement

Recent Stories
Zacks: Alaska Communications Systems Group, Inc. (ALSK) Receives Consensus Rating of “Strong Buy” from Brokerages
Zacks: Hawaiian Telcom Holdco, Inc. (HCOM) Given Average Rating of “Strong Buy” by Analysts
Duerr AG (DUE) Receives Average Recommendation of “Buy” from Analysts
Lanxess AG (LXS) Receives Consensus Rating of “Hold” from Brokerages
Deutsche EuroShop AG (DEQ) Receives Consensus Recommendation of “Buy” from Analysts
Drillisch AG (DRI) Receives Average Recommendation of “Hold” from Brokerages
Talanx AG (TLX) Receives Consensus Rating of “Hold” from Analysts
United Internet AG (UTDI) Receives Consensus Recommendation of “Buy” from Brokerages
Brenntag AG (BNR) Receives Consensus Rating of “Hold” from Analysts
LEG Immobilien AG (LEG) Receives Average Recommendation of “Buy” from Brokerages
Continental AG (CON) Given Average Rating of “Hold” by Analysts
Jenoptik AG (JEN) Receives Average Rating of “Hold” from Brokerages
Wirecard AG (WDI) Given Average Rating of “Buy” by Analysts
ArcelorMittal SA (MT) Receives Average Rating of “Buy” from Brokerages
SAF-HOLLAND S.A. (SFQ) Receives Average Recommendation of “Buy” from Brokerages
Axel Springer SE (SPR) Receives Average Rating of “Hold” from Brokerages
Prosiebensat 1 Media SE (PSM) Receives Average Recommendation of “Buy” from Analysts
Research Analysts Offer Predictions for DTE Energy Company’s FY2018 Earnings (DTE)
Gabelli Equities Analysts Reduce Earnings Estimates for MGM Resorts International (MGM)
RELM Wireless (RWC) to Repurchase 500,000 Shares

OncoSec Medical Incorporated (ONCS) Rating Reiterated by Noble Financial
June 15th, 2017 • 0 comments • Filed Under • by ABMN Staff
inShare

OncoSec Medical logoOncoSec Medical Incorporated (NASDAQ:ONCS)‘s stock had its “buy” rating restated by equities research analysts at Noble Financial in a research report issued to clients and investors on Wednesday.

ONCS has been the topic of several other research reports. Maxim Group reiterated a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research report on Friday, May 12th. HC Wainwright set a $6.00 price objective on OncoSec Medical and gave the stock a “buy” rating in a research report on Monday, May 22nd. Finally, ValuEngine cut OncoSec Medical from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $5.67.
Get OncoSec Medical Incorporated alerts:

Analyst Recommendations for OncoSec Medical (NASDAQ:ONCS)

OncoSec Medical (ONCS) traded down 1.87% during midday trading on Wednesday, reaching $1.05. 121,685 shares of the company’s stock were exchanged. The company’s market cap is $22.23 million. OncoSec Medical has a 12 month low of $0.88 and a 12 month high of $2.08. The company has a 50 day moving average price of $1.07 and a 200 day moving average price of $1.24.

OncoSec Medical (NASDAQ:ONCS) last posted its quarterly earnings data on Thursday, June 1st. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.06. On average, equities analysts anticipate that OncoSec Medical will post ($1.04) EPS for the current year.

A hedge fund recently raised its stake in OncoSec Medical stock. Vanguard Group Inc. boosted its stake in OncoSec Medical Incorporated (NASDAQ:ONCS) by 34.4% during the first quarter, according to its most recent filing with the SEC. The firm owned 564,106 shares of the biotechnology company’s stock after buying an additional 144,325 shares during the period. Vanguard Group Inc. owned 2.70% of OncoSec Medical worth $722,000 at the end of the most recent quarter. 8.88% of the stock is owned by institutional investors and hedge funds.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

GLTA

HCIT